CN101371141A - 调节细胞表面受体预防或减少炎症的方法 - Google Patents

调节细胞表面受体预防或减少炎症的方法 Download PDF

Info

Publication number
CN101371141A
CN101371141A CNA2007800021913A CN200780002191A CN101371141A CN 101371141 A CN101371141 A CN 101371141A CN A2007800021913 A CNA2007800021913 A CN A2007800021913A CN 200780002191 A CN200780002191 A CN 200780002191A CN 101371141 A CN101371141 A CN 101371141A
Authority
CN
China
Prior art keywords
indicator
cell
bacterium
group
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800021913A
Other languages
English (en)
Inventor
P·斯里尼瓦桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38017086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101371141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of CN101371141A publication Critical patent/CN101371141A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

本发明包括区分口腔菌种，以确定该菌种是否口腔有害的方法。该方法包括将一种口腔菌的至少一株细菌或细菌某部位与牙龈细胞接触；然后检测指示化合物是否存在。指示物质基本上不存在，表示该菌种无害。本发明也包括鉴定试剂抗炎效果的方法。该方法包括将细胞与试剂在有害菌或该菌某部位存在情况下进行接触，然后检测指示化合物是否存在。指示物质基本上不存在，表示该试剂是抗炎剂。

Description

调节细胞表面受体预防或减少炎症的方法
相关申请的交叉参考
本申请要求享有2006年1月10日申请的美国临时专利申请系列号60/757,751的相关权益，其内容并入本文作为参考。
发明背景
据认为，哺乳动物口腔软组织显示出最早的炎症迹象。该炎症的总体低水平，可导致牙龈炎和/或牙周炎。据认为，该炎症通常由，或者至少部分由口腔细菌所引起的。此外，口腔组织炎症也能由外科手术、局部损伤、创伤、坏死、不当口腔保健、或者各种系统源而引起。
通常认为，这些疾病和症状所涉及细胞成分包括上皮组织、牙龈成纤维细胞和循环性白细胞，它们都在宿主对细菌产生病原因子的应答中起作用。这些口腔感染所涉及的一些细菌病原是已知的，尽管许多的病原仍未知或仍不明确。虽然某类细菌感染，通常是许多该类口腔疾病的发病原因，但是疾病状态或症状的病理，却是由宿主应答所介导。使用抗菌剂可减少某口腔菌群，同时也可使炎症减轻。然而，该方法也有缺点，因为该杀菌并不加以区分(有益口腔菌和有害口腔菌都被杀灭)，而且该杀菌对剂量和时间敏感。
口腔组织的细菌感染可刺激宿主的免疫应答，并通过上调可导致重要组织损伤的炎症介质而减缓治愈过程。这些代谢物作为主要介质而在牙龈炎、牙周炎、骨髓炎、和其它炎症疾病中发生。
据报道炎症机理之一，是通过哺乳动物细胞某跨膜受体介导。例如，toll-样受体(“TLRs”)是糖基化的跨膜蛋白，其一旦被配体诱导的寡聚化激活，将可在细胞内引发免疫应答，并最终导致介导炎症状态的细胞因子、白介素和其它分子的表达。
本领域需要用于这样的炎症效应诊断、治疗和预防的试剂和技术。
附图简述
图1是显示细胞表面与微生物接触的示意图。
图2显示了toll-样受体(TLR)1，2，3，4，5，6，7和9的信号途径，以及各TLR调节所产生的各种分子。
发明简述
本发明包括对口腔菌种进行区分，以确定该菌种是否为口腔有害的方法。该方法包括将一种口腔菌的至少一株细菌或细菌某部位与牙龈细胞接触；然后检测指示化合物是否存在。指示物质基本上不存在，表示该菌种无害。
本发明范围也包括确定试剂抗炎效果的方法。该方法包括将细胞与试剂在有害菌或该菌某部位存在情况下进行接触，然后检测指示化合物是否存在。指示物质基本上不存在，表示该试剂是抗炎剂。
发明详述
本发明提供了(1)区分有害菌和有益口腔菌的方法，和(2)确定特定试剂抗炎效果的方法。本发明也提供了在细胞中用三氯生(triclosan)阻止toll-样受体调节的方法。
本文所用的“炎症”是指由组织损伤或破坏所引发的局部保护反应，其通常可破坏、稀释或掩蔽损伤介质和受损组织。在急性症状中，它以疼痛、发热、红肿和肿胀为特征。在组织学上，炎症涉及一系列复杂事件，包括随着渗透压和血流的增加，小动脉、毛细管和小静脉膨胀；含血浆蛋白的流体渗出，以及白细胞至炎症位点迁移。炎症可相应于，促炎细胞介质或诸如抗原抗体相互作用或抗原与敏化淋巴细胞间作用所释放的物质的水平增加。广而言之，抗炎剂是与不用试剂处理的同样细胞相比，其可减少这些细胞组织效应的性质和/或程度的任何试剂。
一方面，本发明提供了评估细菌的特定种或株，以确定该种或株是否为口腔有害的方法。“有害”，它意味着病原菌，其存在可通过所感染细胞产生炎症介质。一些细菌株/种据报道是有害的，包括下文表I所示：
表1：据报道有害的口腔菌
 
戈氏放线菌(A.gerencseriae)
内氏放线菌1(A.naeslundii 1)
内氏放线菌2(A.naeslundii 2)
小韦荣球菌(V.parvula)
缓症链球菌(S.mitis)
口腔链球菌(S.oralis)
牙龈二氧化碳嗜纤维菌(C.gingivalis)
生痰二氧化碳噬纤维菌(C.sputigena)
具核梭杆菌具核亚种(F.nucleatum ss nucleatum)
具核梭杆菌多型亚种(F.nucleatum ss polymorphum)
牙周梭杆菌(F.periodonticum)
中间普雷沃菌(P.intermedia)
连翘坦纳菌(T.forsythia)
口颊纤毛菌(L.buccalis)
粘膜奈瑟氏菌(N.mucosa)
痤疮丙酸杆菌(P.aenes)
产黑色素普雷沃菌(P.melaninogenica)
有毒月单胞菌(S.noxia)
本方法包括将待测口腔菌种或菌株的至少一个细菌，与至少一个牙龈细胞接触。可选地，将牙龈细胞与细菌某部位，细胞膜，胞浆物，细菌代谢物、终产物或副产物，和/或毒力因子接触。
该步骤可体外进行，例如，维持培养细菌或细菌某组成部位及牙龈细胞，然后将该培养物予以组合。可选地，将细菌培养物以合适递送载体施用于口腔，从而将该接触在体内进行。
在该接触之后，检测一种或多种指示剂物质。这样的指示剂包括常规宿主免疫应答过程所产生的已知或待发现的任何物质，其包括涉及在细胞产生细胞因子和其它促炎介质过程中的中间化合物，酶，蛋白，RNAs，DNAs，和其它分子。优选地，指示剂是由任何toll-样受体(例如如图2所示)，诸如包括TLRs2，3，4，5，7，和9调节所产生的那些指示剂物质；NFκ-B途径的分子，细胞因子，白介素(例如1，6，8，12)，肿瘤坏死因子(TNF)，肽酶，以及白介素或TNF亚单位和/或白介素、趋化因子(例如CCL5，CCL4，CCL3，和CC10)及基质金属蛋白酶的编码mRNAs。
所选指示物质的检测，可用本领域已知或待发展的任何方式进行，并且该检测可以是相对或者绝对的测量。检测可通过直接定量检测所选指示物质进行。可选地，检测可用其它检测系统间接检测完成，例如使用放射性和/或荧光标记，抗体，特异性基因基因表达水平的改变，mRNA分析，微阵列分析，和/或抗氧化状态的改变。例如，如果该指示剂是一种酶，那么就可将该样品置于合适的底物，然后检测该酶催化反应的终产物以确定该酶指示剂是否存在。在本发明情况下，所选指示物质基本上不存在，意味着该菌种/菌株无害，即其不以引发任何促炎介质产生的方式影响细胞。
本发明也包括评估特定试剂抗炎能力或效果的方法，即，该试剂减少或消除暴露于病原菌的组织中的炎症的能力。该方法包括对待测试剂进行筛选。这样的试剂可以是蛋白，肽，有机分子，无机分子，或任何所述分子的复合物。
在某些情况下，期望所选待测试剂在口腔环境中不显示显著的杀菌效应。例如，该试剂可从显示最小抑制浓度(MIC)为0，少于约5％，少于约10％，少于约20％，以及少于约30％的物质中选取。
MIC研究通常包括在合适的溶剂中制备活性试剂溶液，以及溶液活性试剂的后续系列稀释。将所选细菌的标准悬液(这可能是某个细菌范围，每种细菌都有其特定生长和处理方案)，加至各浓度的稀释活性试剂中。细菌和活性试剂在37℃和适宜条件下温育，典型地，温育48小时后检测细菌的生长。
MIC研究对照，包括在任何所加溶剂或赋形剂缺乏情况下，监测细菌生长的生长对照。其它对照，可监测实验所用介质的无菌状态。用于将活性试剂溶解的溶剂对细菌的效应，是在该研究中包括的最后系列对照。
温育后，将培养皿置于微皿光谱光度计610nm处读数。以抑制细菌生长的最低活性试剂浓度，读取结果。在高活性浓度下，细菌将不会生长(显示出低光密度读数)，在低活性浓度下，细菌则会扩增(显示出高光密度读数)。阻止细菌生长的最低活性浓度，定义为MIC。对照应该为如下结果：
无菌介质——无细菌生长
所监测细菌的生长——培养基显示出繁密的生长
用于溶解活性试剂的溶剂，不应抑制细菌(因为它们必须本质上无害)。
评估特定试剂抗炎能力或效果的方法，包括将细胞与病原菌或有害菌进行接触的步骤。待接触细胞可以在体外或体内，可以是原核的或真核的，也可获自细胞培养系或临床样品。
用于本方法的合适病原菌或有害菌，可包括以引发免疫应答的方式，影响所选细胞的任何本领域已知或待发现的细菌。这样的细菌可以包括，例如上文表I所示的那些。
评价特定试剂抗炎能力或效果的方法，也包括检测一种或多种指示化合物是否存在的步骤。指示化合物及检测方法和体系，可以是任意上文所述的那些。
本发明也包括含有通过上文实验发现显示抗炎效应的试剂的口腔制剂，以及通过将口腔组织细胞与三氯生接触，阻止该口腔组织细胞上toll-样受体调节的方法。
本发明也包括通过给组织以次-MIC浓度/据次-MIC浓度，施用化合物例如三氯生，来减少或预防口腔组织炎症的方法。

Claims (26)

1.区分口腔菌种的方法，该方法包括：
(a)将一种口腔菌的至少一种细菌或某细菌部位，与牙龈细胞接触；以及
(b)检测指示化合物是否存在
其中，指示剂基本上不存在表示该菌种无害。
2.权利要求1的方法，其中牙龈细胞是在体外。
3.权利要求1的方法，其中牙龈细胞是在哺乳动物的口腔原位。
4.权利要求1的方法，其中指示剂选自toll-样受体调节所产生分子组成的组。
5.权利要求1的方法，指示剂选自TLR2，TLR3和TLR4调节所产生分子组成的组。
6.权利要求1的方法，指示剂选自TLR5，TLR7和TLR9调节所产生分子组成的组。
7.权利要求1的方法，其中指示剂选自NF-κB途径分子组成的组。
8.权利要求1的方法，其中指示剂选自细胞因子和白介素组成的组。
9.权利要求1的方法，其中指示剂选自IL-1，IL-6，IL-8，IL-12和TNF-α组成的组。
10.权利要求1的方法，其中指示剂被直接检测。
11.权利要求1的方法，其中指示剂被间接检测。
12.权利要求1的方法，其中至少一种细菌获自临床样品。
13.鉴定试剂抗炎效果的方法，该方法包括将细胞与试剂在有害菌或该菌某部位存在情况下进行接触，然后检测指示剂化合物是否存在，
其中，指示剂基本上不存在表示该试剂是抗炎剂。
14.权利要求13的方法，其中细胞是真核细胞。
15.权利要求13的方法，其中细胞是原核细胞。
16.权利要求13的方法，其中指示剂选自toll-样受体调节所产生分子组成的组。
17.权利要求13的方法，其中指示剂选自TLR2，TLR3，TLR4，TLR5，TLR7和TLR9调节所产生分子组成的组。
18.权利要求13的方法，其中指示剂选自NF-κB途径分子组成的组。
19.权利要求13的方法，其中指示剂选自细胞因子和白介素组成的组。
20.权利要求13的方法，其中指示剂选自IL-1，IL-6，IL-8，IL-12和TNF-α组成的组。
21.权利要求13的方法，其中指示剂分子被直接检测。
22.权利要求13的方法，其中所述试剂选自MIC约少于20％的试剂。
23.阻止哺乳动物口腔细胞中toll-样受体调节的方法，该方法包括将受体与三氯生接触。
24.权利要求23的方法，其中所述细胞是牙龈细胞。
25.权利要求23的方法，其中toll-样受体选自TLR2，TLR3，TLR4，TLR5，TLR7和TLR9。
26.减少或预防口腔组织炎症的方法，该方法包括以一定浓度给口腔组织施用含三氯生的组合物，以使对组织施用的三氯生达到次-MIC水平。
CNA2007800021913A 2006-01-10 2007-01-08 调节细胞表面受体预防或减少炎症的方法 Pending CN101371141A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75775106P 2006-01-10 2006-01-10
US60/757,751 2006-01-10

Publications (1)

Publication Number Publication Date
CN101371141A true CN101371141A (zh) 2009-02-18

Family

ID=38017086

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800021913A Pending CN101371141A (zh) 2006-01-10 2007-01-08 调节细胞表面受体预防或减少炎症的方法

Country Status (18)

Country Link
US (1) US9157914B2 (zh)
EP (2) EP1971865B1 (zh)
JP (2) JP2009523029A (zh)
CN (1) CN101371141A (zh)
AR (1) AR058959A1 (zh)
AU (1) AU2007204730B2 (zh)
BR (1) BRPI0706505A2 (zh)
CA (2) CA2635605C (zh)
DK (2) DK2177621T3 (zh)
ES (2) ES2431291T3 (zh)
HK (2) HK1121235A1 (zh)
MY (1) MY151118A (zh)
PH (1) PH12014501163A1 (zh)
PL (2) PL1971865T3 (zh)
RU (1) RU2431845C2 (zh)
TW (2) TW201415028A (zh)
WO (1) WO2007082181A2 (zh)
ZA (1) ZA200805730B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431291T3 (es) * 2006-01-10 2013-11-25 Colgate-Palmolive Company Métodos para modular receptores de superficie celular para prevenir o reducir la inflamación
AR076177A1 (es) 2009-04-01 2011-05-26 Colgate Palmolive Co MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL
RU2526912C2 (ru) 2009-04-01 2014-08-27 Колгейт-Палмолив Компани Композиции карбонатных соединений, препятствующих образованию биопленки, для использования при уходе за полостью рта
TWI481870B (zh) * 2009-04-01 2015-04-21 Colgate Palmolive Co 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記
MY170956A (en) 2009-04-01 2019-09-20 Colgate Palmolive Co Menthol-derivative compounds and use thereof as oral and systemic active agents
CN107636464B (zh) 2015-05-06 2020-08-11 宝洁公司 口腔中微生物毒力因子的解毒
US9964472B2 (en) 2016-06-29 2018-05-08 The Procter & Gamble Company Methods for sampling gingival metabolites
CN115298546A (zh) * 2020-04-02 2022-11-04 高露洁-棕榄公司 用于中和脂多糖毒性的组合物和方法和鉴定脂多糖毒性的方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538230A (en) * 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US4358437A (en) * 1978-11-29 1982-11-09 Beecham Group Limited Compositions
US5288480A (en) * 1987-01-30 1994-02-22 Colgate-Palmolive Co. Antiplaque antibacterial oral composition
GB9117140D0 (en) * 1991-08-08 1991-09-25 Unilever Plc Treatment of periodontitis
DE4226043A1 (de) * 1992-08-06 1994-02-10 Haarmann & Reimer Gmbh Mittel mit physiologischem Kühleffekt und für diese Mittel geeignete wirksame Verbindungen
CA2176237A1 (en) * 1993-11-10 1995-05-18 Richard P. Darveau Treatment of bacterially-induced inflammatory diseases
US5578295A (en) * 1995-04-28 1996-11-26 The Procter & Gamble Company Oral care compositions comprising certain substituted diphenyl ethers
AUPN627595A0 (en) 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
EP0935454B1 (de) 1996-06-12 2001-08-22 Cognis Deutschland GmbH Kosmetische und/oder pharmazeutische zubereitungen
EP0863402B1 (en) 1997-03-03 2005-09-14 Amersham Biosciences UK Limited In-situ cell extraction and assay method
JP2000128900A (ja) 1998-10-26 2000-05-09 Japan Science & Technology Corp 新規トル様（Ｔｏｌｌ−ｌｉｋｅ）レセプター及びその遺伝子
FR2794457B1 (fr) 1999-06-01 2001-08-10 Oreal Derives carbonates de retinol, procede de preparation et utilisations
EP2295968B1 (en) 1999-12-03 2012-09-19 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
GB0001704D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
US20020009740A1 (en) * 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6500409B1 (en) 2000-05-10 2002-12-31 Colgate Palmolive Company Synergistic antiplaque/antigingivitis oral composition
DE10059584A1 (de) 2000-11-30 2002-06-06 Beiersdorf Ag Kosmetische oder dermatologische getränkte Tücher
BR0116606A (pt) 2000-12-29 2006-05-09 Reddy Us Therapeutics Inc métodos e composições para detecção de compostos que modulam as respostas inflamatórias
JP2004534841A (ja) 2001-07-09 2004-11-18 コンビナトアールエックス インコーポレーティッド 炎症疾患の治療のための組合せ
US6893828B2 (en) 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof
EP1499898A2 (en) 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US7005225B2 (en) * 2002-11-12 2006-02-28 Samsung Electronics Company Organosol including amphipathic copolymeric binder having crystalline material, and use of the organosol to make dry tones for electrographic applications
EP1599212A4 (en) * 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
GB2401865A (en) 2003-05-22 2004-11-24 Givaudan Sa Antibacterial and antifungal glycerol monocarbonates
US7202234B2 (en) * 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
PT1701978E (pt) * 2003-12-03 2009-03-03 Whitehead Biomedical Inst Utilização de caderina-t solúvel no tratamento de distúrbios metabólicos
JP2005304365A (ja) 2004-04-20 2005-11-04 Japan Science & Technology Agency Ｔｌｒリガンド及びｉｌ−１応答障害性モデル動物
FI20040572A0 (fi) 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
US20060141421A1 (en) * 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. System and method for detecting substances related to oral health
WO2006074450A2 (en) * 2005-01-07 2006-07-13 President And Fellows Of Harvard College Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
ES2431291T3 (es) * 2006-01-10 2013-11-25 Colgate-Palmolive Company Métodos para modular receptores de superficie celular para prevenir o reducir la inflamación
US20080161394A1 (en) 2006-11-23 2008-07-03 Jean-Yves Fouron Cosmetic composition comprising at least one volatile carbonic acid ester
WO2008093072A2 (en) 2007-01-29 2008-08-07 Paul Webb Topical composition against contact dermatitis due to water
EP2207546A1 (en) 2007-10-09 2010-07-21 Humco Holding Group, Inc. Antifungal treatment of nails

Also Published As

Publication number Publication date
CA2635605A1 (en) 2007-07-19
AU2007204730B2 (en) 2011-11-17
DK1971865T3 (da) 2013-07-08
WO2007082181A2 (en) 2007-07-19
HK1141838A1 (en) 2010-11-19
TW200801514A (en) 2008-01-01
CA2849559A1 (en) 2007-07-19
BRPI0706505A2 (pt) 2011-03-29
PL2177621T3 (pl) 2014-03-31
EP2177621B1 (en) 2013-10-09
ES2421595T3 (es) 2013-09-04
PH12014501163A1 (en) 2015-05-18
CA2635605C (en) 2014-07-08
RU2431845C2 (ru) 2011-10-20
TW201415028A (zh) 2014-04-16
AU2007204730A1 (en) 2007-07-19
EP2177621A2 (en) 2010-04-21
EP2177621A3 (en) 2010-09-08
AR058959A1 (es) 2008-03-05
MY151118A (en) 2014-04-15
PL1971865T3 (pl) 2014-02-28
JP2015051000A (ja) 2015-03-19
EP1971865A2 (en) 2008-09-24
JP2009523029A (ja) 2009-06-18
RU2008132839A (ru) 2010-02-20
HK1121235A1 (en) 2009-04-17
US9157914B2 (en) 2015-10-13
US20070160544A1 (en) 2007-07-12
WO2007082181A3 (en) 2007-09-27
DK2177621T3 (da) 2013-10-28
EP1971865B1 (en) 2013-04-17
ES2431291T3 (es) 2013-11-25
ZA200805730B (en) 2014-12-23

Similar Documents

Publication Publication Date Title
Swimberghe et al. Biofilm model systems for root canal disinfection: a literature review
CN101371141A (zh) 调节细胞表面受体预防或减少炎症的方法
Vianna et al. Effect of root canal procedures on endotoxins and endodontic pathogens
Perry et al. Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN-γ-mediated inhibition
Renvert et al. Topical minocycline microspheres versus topical chlorhexidine gel as an adjunct to mechanical debridement of incipient peri‐implant infections: a randomized clinical trial
Gottumukkala et al. Comparative evaluation of the efficacy of two controlled release devices: Chlorhexidine chips and indigenous curcumin based collagen as local drug delivery systems
Thet et al. SPaCE swab: point-of-care sensor for simple and rapid detection of acute wound infection
Nagase et al. Distinct skin microbiome and skin physiological functions between bedridden older patients and healthy people: a single-center study in Japan
Slade et al. An in vitro collagen perfusion wound biofilm model; with applications for antimicrobial studies and microbial metabolomics
Jenkinson et al. The microbiology of periodontal disease
Wawire et al. Virulence and antimicrobial resistance genes are enriched in the plasmidome of clinical Escherichia coli isolates compared with wastewater isolates from western Kenya
Ke et al. Identification of the antibacterial action mechanism of curcumin on Streptococcus mutans through transcriptome profiling
Antipa et al. Virulence Profiles of Bacterial Strains Isolated From Periodontal Lesions
Fattahi et al. Comparison of mast cell counts between the patients with moderate and severe periodontitis
Adekunle et al. Antibiotic susceptibility pattern of strains of Campylobacter coli isolated in Osogbo, Nigeria
YANG et al. Genomic characterization and antimicrobial susceptibility of bovine intrauterine Escherichia coli and its relationship with postpartum uterine infections
AU2012200945B2 (en) Methods of modulating cell surface receptors to prevent or reduce inflammation
McDermott et al. Gnotobiotic Human Colon Ex Vivo
Chandra Isolation, Identification and Speciation of Diphtheroids from Skin and Soft Tissue Infections and their Antibiotic Susceptibility Pattern
Mulin et al. Clinical and molecular epidemiology of hospital Enterococcus faecalis isolates in eastern France
Trilla et al. A cluster of fever and hypotension on a surgical intensive care unit related to the contamination of plasma expanders by cell wall products of Bacillus stearothermophilus
Kodi et al. URINARY TRACT INFECTION.
Silva Steffens et al. Characterization of progressive periodontal lesions in chronic periodontitis patients: levels of chemokines, cytokines, matrix metalloproteinase-13, periodontal pathogens and inflammatory cells
Ribbon Open prospective study on the topical treatment of interdigital fungal infections in diabetic patients
Patel Evaluation of early wound healing events in a rat wound model treated with" active" topical dressings

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090218